Decoy Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0 | $1.8M |
| Research and development | $368,170 | $770,027 | $7.2M | $15.8M | $8.5M |
| Operating expenses | $12.6M | $5.7M | $12.9M | $31.8M | $14.7M |
| Operating income | -$12.6M | -$5.7M | -$12.9M | -$31.8M | -$12.8M |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$12.5M | -$5.6M | -$12.5M | -$31.6M | -$12.8M |
| Balance Sheet | |||||
| Cash and equivalents | $10.7M | $2.4M | $5.9M | $12.1M | $29.2M |
| Current assets | $11.0M | $3.0M | $6.5M | $14.5M | $30.2M |
| Total assets | $11.1M | $3.0M | $6.6M | $14.7M | $40.8M |
| Current liabilities | $5.2M | $1.5M | — | — | — |
| Total liabilities | $5.2M | $1.5M | $1.3M | $4.3M | $2.1M |
| Stockholders' equity | $5.9M | $1.5M | $5.3M | $10.4M | $38.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$4.8M | -$4.5M | -$12.8M | -$17.6M | -$10.2M |
| Depreciation and amortization | $7,151 | $4,424 | $10,051 | $6,677 | $19,183 |
| Stock-based compensation | $219,058 | $273,730 | $524,838 | $796,803 | $559,044 |
| Capital expenditure | $577,000 | $0 | — | — | $0 |
| Free cash flow | -$5.4M | -$4.5M | — | — | -$10.2M |
| Impairments | $0 | $0 | $0 | $8.9M | $0 |
Shares outstanding 532.0K · Free float 92.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.